On May 10, 2022 BIOASIS TECHNOLOGIES INC.. (TSXV:BTI.V; OTCQB:BIOAF), (the "Company or "Bioasis") a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the "BBB") reported that it has entered into a research collaboration and license agreement with Neuramedy Co Ltd ("Neuramedy") of Seoul, Korea (Press release, biOasis, MAY 10, 2022, View Source [SID1234614207]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Neuramedy is a biotech company researching and developing innovative solutions for neurodegenerative diseases. The company aims to provide disease modifying treatments for Parkinson’s disease and other synuclein related diseases.
Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2. Tomaralimab is currently in development for the treatment of Parkinson’s disease and Multiple System Atrophy.
Bioasis will receive an upfront payment and may receive an additional US$72 million in milestone payments and a royalty on net sales.
"We are excited to have entered into this agreement with Bioasis. We expect the xB3TM platform will improve the efficacy and safety of our Tomaralimab. Through the collaboration with the companies like Bioasis, we hope to provide solutions that can improve the lives of patients with neurodegenerative disorders," said Seung Jae Lee, Ph. D., Neuramedy’s CEO.
"We are very pleased to have entered into this agreement and excited to be working with Neuramedy on this new target for Parkinson’s disease and Alzheimer’s disease. Forming innovative partnerships with companies such as Neuramedy is an important part of our strategy to see the broadest possible uptake of promising technology. Our xB3TM BBB drug delivery platform has the potential to significantly advance the treatment of neurogenerative diseases, solving a major unmet clinical need and improving the lives of patients, said Deborah Rathjen, Ph.D., Bioasis’ Executive Chair.